# Study of Dosage Exploration and Pharmacokinetics for HA121-28 Tablets

> **NCT03994484** · PHASE1 · UNKNOWN · sponsor: **CSPC ZhongQi Pharmaceutical Technology Co., Ltd.** · enrollment: 44 (estimated)

## Conditions studied

- Advanced Solid Tumor

## Interventions

- **DRUG:** HA121-28 tablets
- **DRUG:** HA121-28 tablets
- **DRUG:** HA121-28 tablets
- **DRUG:** HA121-28 tablets
- **DRUG:** HA121-28 tablets
- **DRUG:** HA121-28 tablets
- **DRUG:** HA121-28 tablets
- **DRUG:** HA121-28 tablets

## Key facts

- **NCT ID:** NCT03994484
- **Lead sponsor:** CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2018-10-10
- **Primary completion:** 2022-12-30
- **Final completion:** 2022-12-30
- **Target enrollment:** 44 (ESTIMATED)
- **Last updated:** 2022-02-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03994484

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03994484, "Study of Dosage Exploration and Pharmacokinetics for HA121-28 Tablets". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT03994484. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*